Gates Package — page 25
of 1375 pages
← p.24 p.26 → · this page in the original PDF · package
Availability, Manufacturing Capability
¢
Toyama currently has a stock of 2.8 million tablets in
terms of the 200mg tablet. They correspond to 56,000
treatment courses under the dose regimen for the ongoing Phase 3 clinical studies for influenza (1,800mg
BID on Day 1 followed by 800 mg BID on Day 2 to 5).
Please note the dose regimen for Ebola treatment could
be different than influenza.
¢
Upon request by the Minister of Health, Labor, and
Welfare, our monthly manufacturing capacity is around 8
million tablets.
This is our OCR of the page, with running headers and footers removed. The
Committee's PDF
is authoritative; quote from it. Machine-readable, including the uncleaned
text: /api/page/gates/25
Records on this page
| Record | Date | Type | Pages |
|---|---|---|---|
| gates:email:00005 | 2014-09-17 | 20–26 |